Filing Flows › Comparisons › SNY vs BMY
Sanofi vs Bristol Myers Squibb: SNY and BMY compared
Sanofi is the larger company: $11.6B of revenue in its latest quarter (Q2 2026) against $13.1B for Bristol Myers Squibb (Q3 2026). Sanofi is growing faster (+16% against +7% a year earlier). Bristol Myers Squibb is more profitable, with an operating margin of 19.4% against 9.0%.
Where the money goes: SNY and BMY
Sanofi (SNY) · Q2 2026
Sanofi, Q2 2026: revenue $11.6B (+16% year over year), operating margin 9.0%, net earnings $377M. The chart follows the revenue to costs, profit and cash.
Bristol Myers Squibb (BMY) · Q3 2026
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
| Sanofi (SNY) | Bristol Myers Squibb (BMY) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $11.6B | $13.1B |
| Revenue growth, Y/Y | +16% | +7% |
| Operating margin | 9.0% | 19.4% |
| Net earnings | $377M | $2.2B |
| Net margin | 3.3% | 16.5% |
| Operating cash flow | — | $4.2B |
| Free cash flow | — | $3.8B |
| Market value | — | $127.6B |
| P/E | — | 13.7× |
| Analysts’ mean target | — | $65.25 |
Where the revenue comes from
Bristol Myers Squibb
- Net product sales: $12.6B (97%)
- Camzyos: $420M (3%)
Questions
Which is bigger, Sanofi or Bristol Myers Squibb?
Sanofi is the larger company: $11.6B of revenue in its latest quarter (Q2 2026) against $13.1B for Bristol Myers Squibb (Q3 2026).
Is Sanofi or Bristol Myers Squibb growing faster?
Sanofi is growing faster (+16% against +7% a year earlier).
Which is more profitable, Sanofi or Bristol Myers Squibb?
Bristol Myers Squibb is more profitable, with an operating margin of 19.4% against 9.0%.
More: Sanofi earnings · how Sanofi makes money · Bristol Myers Squibb earnings · how Bristol Myers Squibb makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Jul 30, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.